June 24, 2021 -- Catamaran Bio and Bio-Techne have expanded their collaboration on the development of cell engineering and cell process technologies for Catamaran's manufacturing of chimeric antigen receptor-natural killer (CAR-NK) cell therapies.
Under the collaboration, Bio-Techne will contribute its cell expansion technologies and both companies will contribute expertise to enable large-scale production of functional CAR-NK cells.
Catamaran now has license to Bio-Techne's rights related to the TcBuster transposon system for use in the manufacturing of allogenic cell therapies; it has integrated this system into its CAR-NK Tailwind platform.
The two firms' collaboration began in 2020, they said.
Financial details of the agreement were not disclosed.